Tonghua Dongbao Pharmaceutical Co., Ltd. (SHA:600867)

Market Cap	14.89B
Revenue (ttm)	2.43B
Net Income (ttm)	341.31M
Shares Out	1.93B
EPS (ttm)	0.16
PE Ratio	48.43
Forward PE	33.61
Dividend	0.25 (3.23%)
Ex-Dividend Date	May 23, 2024

Volume	20,921,707
Average Volume	13,137,490
Open	7.70
Previous Close	7.72
Day's Range	7.69 - 7.84
52-Week Range	7.02 - 11.09
Beta	0.27
RSI	57.03
Earnings Date	Apr 30, 2025

About SHA:600867

Tonghua Dongbao Pharmaceutical Co., Ltd. researches and develops, manufactures, and sells pharmaceutical for the treatment of diabetes, endocrine, and cardiovascular and cerebrovascular diseases products in China. It offers human insulin API and injections; insulin glargine API and injections; insulin aspart API and injections; liraglutide injections; zhennaoning capsules; and diabetes-related medical devices. The company also provides insulin pen and needle injection system, blood sugar monitoring system, and online and offline patient managem...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1985
• Employees: 3,196
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600867

Financial Performance

In 2023, SHA:600867's revenue was 3.08 billion, an increase of 10.69% compared to the previous year's 2.78 billion. Earnings were 1.17 billion, a decrease of -26.17%.